Cybin Shares Up Slightly as HELP Backers Focus on Main Trial
Helus Pharma (HELP) shares rose 1.3% to $4.55 Friday in light trading, with no new company updates since April 30. Investors await topline data from the APPROACH Phase 3 trial of HLP003 for major depressive disorder, expected in Q4. Helus ended the year with $195.1 million in cash but posted a $42.7 million quarterly net loss. The FDA has not approved HLP003 or HLP004.
